

Author Index—1994

- Abdel-Dayem, HM, 125(ab)
Abdel-Nabi, H, 120(ab), 121(ab)
Ackermann, R, 108(ab)
Ackermann, RJ, 105(ab), 109(ab)
Ahmad, WM, 191
Akkermans, LMA, 108(ab)
Al-Hani, A, 110(ab)
Amoling, R, 112(ab)
Anderson, B, 119(ab)
Anderson, R, 114(ab)
Archambault, PD124(ab)
Arroyo, A, 122(ab)
Arroyo, AJ, 218
Arthur, JH, 113(ab)
Au, FC, 121(ab)
- Bacharach, SL, 119(ab)
Bag, R, 125(ab)
Baird, T, 106(ab)
Bandyopadhyay, D, 74
Barron, B, 118(ab)
Barrow, SA, 118(ab)
Bartiromo, A, 111(ab)
Bayer, P, 112(ab)
Bayouth, JE, 109(ab)
Behar, M, 129(ab)
Bense, LC, 124(ab)
Bixler, A, 121(ab)
Bjornson, B, 112(ab)
Blais, M, 116(ab)
Bleis-Geis, M, 129(ab)
Blend, MJ, 70, 94
Blondeau, KL, 79
Bloodworth, GA, 126(ab)
Blust, J, 58
Boldizar, SC, 108(ab)
Borchert, R, 111(ab)
Boshko, LA, 121(ab)
Boyce, TM, 2, 48
Brophey, M, 118(ab)
Brostek, W, 125(ab)
Brown, BM, 124(ab)
Brown, ML, 108(ab), 117(ab), 122(ab)
Brown, PH, 106(ab)
Brown, TF, 115(ab)
Budde, PA, 113(ab)
Bugaj, JE, 124(ab)
Burke, TS, 117(ab)
Burriss, T, 112(ab)
Bushman, MJ, 124(ab)
Butler, SP, 113(ab), 119(ab)
- Cacciatore, B, 144, 204
Callahan, RJ, 118(ab)
Caride, VJ, 213
Carlson, C, 129(ab)
Carlson, CM, 111(ab)
Caroline, DF, 121(ab)
Carpenter, S, 213
Cassel, D, 106(ab)
- Chaly, T, 74
Chatterton, BE, 108(ab)
Cheng, KT, 114(ab), 124(ab), 173, 222
Chilton, HM, 261
Christian, C, 124(ab)
Christian, PE, 262
Clarke, M, 255
Close, DW, 250
Coates, GG, 118(ab), 171, 211
Coleman, RE, 94, 120(ab)
Colloms, C, 114(ab), 222
Conti, S, 117(ab)
Corbett, JR, 105(ab), 109(ab)
Corning, P, 110(ab)
Cotton, L, 108(ab)
Cronin, V, 120(ab)
- DaCosta, M, 111(ab)
Dadparvar, S, 107(ab)
Dahl, JR, 74
Dahlbom, M, 108(ab), 111(ab)
DaSilva, JN, 123(ab)
Daube-Witherspoon, ME, 119(ab)
Dávila-Román, VG, 106(ab)
Davis, RT, 112(ab)
Dayton, R, 119(ab)
De Rosch, MA, 124(ab)
Delveccio, A, 118(ab)
Dent, J, 108(ab)
Deutsch, KF, 124(ab)
Devlin, K, 117(ab)
Dey, HM, 115(ab)
Diaz, E, 125(ab)
Diaz, M, 109(ab)
Diggles, L, 111(ab), 128(ab), 165
Dillehay, GL, 109(ab)
Dillon, W, 119(ab)
Donaghy, TA, 113(ab), 119(ab)
Donohoe, ME, 21
Drabkin, D, 129(ab)
Dragotakis, SC, 118(ab)
Duncan, K, 240
Dunn, WL, 106(ab)
Duxbury, M, 119(ab)
Dworkin, H, 225
- Eades, CG, 115(ab)
Early, PJ, 250
Edelbroek, MAL, 108(ab)
Eisenberg, B, 107(ab), 118(ab), 171, 211
Erb, D, 120(ab)
Eshima, D, 112(ab)
- Faber, TL, 145
Fahey, FH, 115(ab)
Fain, RL, 104(ab)
- Faith, B, 121(ab)
Fang, B, 118(ab)
Farley, CP, 126(ab)
Farley, JA, 112(ab)
Farooqui, M, 110(ab)
Feldkamp, MJ, 35
Fellows, CL, 171
Fernandez, M, 129(ab)
Fernandez, NL, 129(ab)
Ficaro, E, 108(ab)
Ficaro, EP, 105(ab), 109(ab)
Ficken, V, 205
Fischer, G, 112(ab)
Fischer, S, 112(ab)
Fischman, AJ, 118(ab)
Folks, RD, 145
Foster, ME, 21
Fratkin, M, 109(ab)
Fratkin, MJ, 113(ab)
Frawley, PC, 14, 107(ab)
Fukuchi, K, 104(ab)
- Gage, HD, 115(ab)
Galantowicz, P, 121(ab)
Garcia, E, 112(ab)
Garrison, DA, 106(ab)
Gaskill, M, 120(ab)
Gass, MA, 171, 211
Gebhard, MW, 178
Gentilcore, R, 117(ab)
Georgiou, M, 125(ab), 129(ab)
Gerbaudo, VH, 129(ab)
Geyer, MC, 113(ab)
Gibbons, DL, 115(ab)
Gibbons, RJ, 17, 105(ab)
Glajch, JL, 21
Glynn, RB, 17, 105(ab)
Gona, J, 110(ab), 121(ab)
Goodman, MM, 112(ab)
Gordon, L, 114(ab), 124(ab), 173
Gorham-Ostrom, P, 117(ab)
Gravelle, DR, 116(ab)
Green, JM, 21
Green, SL, 119(ab)
Groch, MW, 110(ab)
Gropler, RJ, 106(ab)
Gross, GP, 110(ab), 123(ab)
Gross, K, 112(ab), 232
Guan, Y, 128(ab)
Gutkowski, R, 225
- Habbab, N, 125(ab)
Hackett, MT, 14, 107(ab), 109(ab), 113(ab), 117(ab), 122(ab)
Hahn, K, 112(ab)
Hahnemann, AR, 107(ab)
Halama, JR, 109(ab)
Hall, A, 255
- Hallendorff, J, 262
Hamblen, SM, 120(ab)
Harkness, BA, 115(ab)
Hart, JW, 121(ab)
Haseman, MK, 127(ab)
Hashimoto, K, 104(ab)
Hauser, MF, 124(ab)
Hawk, TC, 120(ab)
Haymond, D, 222
Haymond, DJ, 114(ab)
Hendel, RC, 113(ab)
Henkin, RE, 109(ab)
Heo, J, 106(ab)
Herold, TJ, 110(ab)
Herzog, SA, 122(ab)
Hiam, J, 42, 43
Hichwa, RD, 115(ab)
Higgins, D, 255
Higgins, W, 122(ab)
Hirschowitz, J, 111(ab)
Hoh, C, 129(ab)
Hoh, CK, 108(ab), 111(ab), 129(ab)
Hollar, BS, 114(ab), 124(ab)
Hoory, S, 74
Hope, E, 129(ab)
Hori, M, 104(ab)
Horowitz, M, 108(ab)
Houle, S, 120(ab), 123(ab)
Hung, JC, 17, 39, 105(ab), 106(ab), 110(ab), 113(ab), 114(ab), 123(ab), 124(ab), 178, 229
Hussey, D, 120(ab), 123(ab)
Hutchins, GD, 104(ab)
- Ichise, M, 123(ab)
Intenzo, C, 110(ab)
Iskandrian, AS, 106(ab)
- Jabir, M, 129(ab)
Jacobs, M, 111(ab)
Jacobson, AF, 122(ab)
Jadali, F, 121(ab)
Jai, H-m, 114(ab)
Jenkins, T, 122(ab)
Johnson, D, 106(ab)
Johnston, DL, 105(ab)
Jolles, PR, 14, 107(ab), 113(ab)
Jones, KL, 108(ab)
Juni, J, 120(ab)
- Kamada, T, 104(ab)
Kapur, S, 120(ab)
Karesh, S, 114(ab)
Karp, JS, 120(ab)
Kasi, LP, 109(ab)
Keim, P, 27, 182
Kemel, A, 114(ab)
Kempf, J, 125(ab)
Keyes, JW Jr, 115(ab)
- Khalkhali, I, 111(ab), 165
Khedkar, N, 63
Kim, EE, 109(ab)
Kim, SM, 110(ab)
Kistenmacher, S, 117(ab)
Kletzky, OA, 118(ab)
Koeppel, JA, 115(ab)
Koller, D, 121(ab)
Kondas, D, 120(ab)
Kozuka, T, 104(ab)
Kreft, A, 109(ab)
Kreitzer, R, 111(ab)
Kronmal, SL, 115(ab)
Kuffer, S, 129(ab)
Kusuoka, K, 104(ab)
- Lambert, K, 107(ab)
Lamki, L, 118(ab)
Lee, FT, 118(ab)
Lee, H, 111(ab)
Lee, ME, 171
Lemons, SM, 126(ab)
Linck, J, 117(ab)
Lipszyc, H, 111(ab)
Liu, B, 114(ab)
Lockwood, A, 121(ab)
Longford, CPD, 112(ab)
Lorberboym, M, 188
Lowe, VJ, 120(ab)
Lyster, D, 119(ab)
- Macey, DJ, 109(ab)
MacFarlane, D, 108(ab)
Machac, J, 111(ab), 121(ab)
Madsen, MT, 3
Magoun, S, 112(ab), 232
Mahoney, DW, 105(ab)
Maier, WP, 121(ab)
Malhi, BS, 122(ab)
Manatt, CJ, 127(ab)
Mantil, J, 111(ab)
Marciano, D, 108(ab), 129(ab)
Marcus, C, 128(ab)
Margouleff, D, 74
Marmion, ME, 124(ab)
Martinez, C, 63
Matacchieri, R, 74
Matsuda, S, 104(ab)
Mattar, AG, 116(ab)
Maurer, AH, 121(ab)
Mayle, L, 255
Mazza, S, 119(ab)
Mazza, SN, 115(ab)
McCartney, W, 205
McCormick, V, 120(ab)
McDonald, H, 122(ab)
McDonald, J, 106(ab)
McKay, E, 119(ab)
Meehan, DA, 120(ab)
Meisner, PD, 124(ab)
Mena, I, 111(ab), 118(ab), 165
Mendez, R, 125(ab)

Meyers, A, 65, 68, 232
 Minn, H, 108(ab)
 Montanaro-Sebal, A, 255
 Morozumi, T, 104(ab)
 Morris, JL, 127(ab)
 Morrissey, GJ, 116(ab)
 Muecke, T, 108(ab)
 Mullan, BP, 108(ab), 178
 Murthy, S, 121(ab)
 Muzinic, M, 111(ab)

Nabi, HA, 110(ab)
 Narveson, LG, 17
 Nelson, J, 122(ab)
 Newman, MA, 97, 194
 Ng, C, 119(ab)
 Ng, CK, 115(ab)
 Nishimura, T, 104(ab)
 Nobrega, JN, 123(ab)

O'Connor, MK, 49
 O'Donoghue, JP, 116(ab)
 Oswald, WM, 123(ab)
 Owens, TP, 105(ab)
 Oxley, K, 125(ab)

Packard, AB, 112(ab)
 Park, CH, 110(ab)
 Park, H-M, 240
 Patel, B, 70
 Patel, J, 110(ab)
 Paul, TG, 123(ab)

Payne, M, 118(ab)
 Peller, PJ, 63
 Perdikaris, N, 109(ab), 122(ab)
 Perry, KM, 104(ab)
 Pescatore, F, 125(ab)
 Peters, J, 125(ab)
 Pfeifer, T, 117(ab)
 Phegley, D, 117(ab)
 Pickett, MW, 40, 79, 95, 192, 263
 Pinon, J, 129(ab)
 Pitt, SR, 105(ab), 109(ab)
 Podoloff, DA, 109(ab)
 Polulak, D, 112(ab)
 Porter, WC, 225
 Posner, MC, 122(ab)
 Prekeges, JL, 107(ab), 118(ab)
 Price, K, 107(ab)
 Pron, GE, 123(ab)
 Purnell, C, 117(ab)

Quinn, C, 117(ab)
 Quinn, RJ, 113(ab), 119(ab)
 Quint, RH, 124(ab)

Rakowski, JT, 218
 Ranger, N, 117(ab)
 Ranger, NT, 108(ab), 122(ab)

Ratica, DM, 108(ab)
 Ratliff, C, 121(ab)
 Reed, NL, 127(ab)
 Reilly, K, 107(ab)
 Reiman, RE, 94
 Rembish, RA, 115(ab)
 Rich, DA, 115(ab)
 Richmond, JCW, 115(ab)
 Riddervold, SJ, 126(ab)
 Riggan, SL, 120(ab)
 Rihela, T, 119(ab)
 Roemer, JR, 115(ab)
 Rubin, PJ, 106(ab)
 Rubin, RH, 118(ab)
 Ruffin, TT, 122(ab)
 Russell, J, 107(ab)
 Russell, JK, 106(ab)
 Ryan, A, 117(ab)
 Ryan, JA, 118(ab)

Sajdak, R, 114(ab)
 Salvatore, M, 111(ab)
 Satter, M, 111(ab)
 Schuetz, TA, 122(ab)
 Seever, RH, 70
 Sfakianakis, GN, 125(ab), 129(ab)
 Shattuck, L, 112(ab)
 Sheppard, MS, 124(ab)
 Shih, W-J, 112(ab), 232
 Sicuro, PL, 171, 211
 Silberstein, EB, 39, 229

Slizofski, W, 107(ab)
 Smart, RC, 113(ab), 119(ab)
 Smith, RJ, 120(ab)
 Soufer, R, 107(ab), 115(ab), 117(ab), 118(ab), 119(ab)
 Speedie, C, 117(ab)
 Spicer, KM, 114(ab), 173
 Spiegler, E, 121(ab)
 Spies, SM, 113(ab)
 Spies, WG, 113(ab)
 Steves, AM, 79
 Stipp, V, 112(ab), 232
 Suarez, M, 117(ab)
 Sun, WM, 108(ab)

Taggart, TR, 106(ab)
 Takamiya, Y, 110(ab)
 Thomas, C, 118(ab)
 Thomas, MI, 127(ab)
 Thompson, RT, 117(ab)
 Tittle, L, 111(ab)
 Treves, ST, 112(ab)
 Truong, KC, 129(ab)
 Turkington, TG, 120(ab)
 Turner, FE, 106(ab)

Uehara, T, 104(ab)
 Ulanski, JS, 112(ab)

Vallabhajosula, S, 111(ab)

Vines, DC, 123(ab)

Wagner, L, 118(ab)
 Wagner, RH, 109(ab)
 Wahl, RL, 108(ab)
 Walsh, D, 225
 Warton, K, 121(ab)
 Watkins, GL, 115(ab)
 Webb, EG, 124(ab)
 Wehmeier, C, 117(ab)
 Weiss, S, 1, 47, 143, 203
 Wierzbinski, B, 112(ab), 232
 Wieseler, JF, 108(ab), 178
 Wilson, D, 120(ab), 123(ab)
 Wilson, ME, 178, 229
 Wintch, K, 65, 68
 Wiseman, GA, 106(ab)
 Wittry, M, 117(ab)
 Wolfangel, RG, 124(ab)
 Wolfe, CA, 126(ab)
 Wollan, PC, 105(ab)
 Woo, S, 129(ab)

Yamagami, H, 104(ab)
 Yasillo, NJ, 115(ab)
 Yoshizumi, T, 107(ab), 117(ab), 118(ab), 119(ab)

Zhang, JJ, 110(ab)
 Zimmer, AM, 113(ab)

Subject Index—1994

- Acceptance testing**, gamma camera, 58
- Accreditation**, nuclear medicine technology programs, 236
- Acetazolamide**, common nonradioactive pharmaceutical listing, 240
- Adenosine**, common nonradioactive pharmaceutical listing, 240
- Anticoagulants**, use in red blood cell kit, 178
- Antral motility**, scintigraphic and manometric evaluation, 108(a)
- ARCnet**, use in nuclear medicine, 49
- Artifacts**
pinhole thyroid images, quality control and, 109(a)
SPECT improvement, 35
- Attenuation correction**
FDG brain scans, 115(a)
PET
F18-FDG, pros and cons, 120(a)
improper contour placement in, 120(a)
optimum scan length, 119(a)
- Bladder**, activity, anterior and posterior planar imaging, 129(a)
- Blood-labeling system**, prevention of cross-contamination and misadministration, 225
- Blood pool imaging**, gated
needleless technique of Tc-99m RBC kit, 106(ab)
planar versus SPECT, 106(ab)
- Bone**
painful metastases, Sr-89 therapy in, 39(le)
scintigraphy, finding of gastrointestinal bleeding on, 14
- Bone agent**, extraosseous uptake of, finding of gastrointestinal bleeding, 14
- Bone metastasis**
pain relief, Sr-89 chloride, 126(a)
SPECT versus planar sensitivity in detection of, 126(a)
- Bone scans**, extraosseous activity, technical considerations in, 107(a)
- Book reviews**
Basic Medical Techniques and Patient Care for Radiologic Technologists, 262
Handbook of Nuclear Medicine, Second Edition, 94
Limitation on Exposure to Ionizing Radiation, 94
- Bothanecol**, common nonradioactive pharmaceutical listing, 240
- Brain**
retention mechanism, Tc-99m labeled radiopharmaceuticals, 114(a)
SPECT images, automated iterative 3-dimensional, 108(a)
- Breast cancer**
high resolution nuclear mammography camera, Tl-201 and Tc-99m SESTAMIBI, 121(a)
scintimammography, prone-dependent, 165
Tc-99m MDP scintigraphy in diagnosis, technician role in, 111(a)
- Breast-pock sign**, radionuclide uptake, 211
- Calibration**, PET, quality assurance procedures, 182
- Cancellation**, Tl-201 chloride myocardial SPECT, 232
- Cancer**, F18-FDG scans, septumless scanner, 120(a)
- Captopril**, common nonradioactive pharmaceutical listing, 240
- Carbon-11**, evaluation, linearity of radionuclide dose calibrators, 74
- Cardiac defibrillator**, automatic internal, infection, Ga-67 citrate detection, 171
- Cardiac stress testing**, quality assurance, 105(ab)
- Cardiomyopathy**, ischemic, dobutamine PET and echocardiography for, 106(ab)
- Cholecystokinin**, common nonradioactive pharmaceutical listing, 240
- Chromate-51**, red cell mass, radioisotopic determination of, 188
- Chromatography**
evaluation of Tc-99m tetrofosmin, 113(a)
thin-layer, characterization of Tc-99m bicsate, 21
- Chronic obstructive pulmonary disease**
pulmonary function testing of, nuclear cardiology laboratory, 105(ab)
Xe-133 washout evaluation of pulmonary function in, 113(a)
- Cimetidine**, common nonradioactive pharmaceutical listing, 240
- Colon**, cancer, Tc-99m monoclonal antibody injection, comparative study, 120(a)
- Colorectal carcinoma**, In-111 monoclonal antibody scans for, false positive findings during, 110(a)
- Components of Preparedness**, NMTCB examination, 79
- Comprehension**, NMTCB examination, 79
- Computed tomography (CT)**, normal or equivocal, positive liver SPECT images correlated with, 65
- Computers**
acquisition of nuclear medicine images, 3
automation of nuclear medicine operation, 110(a)
networks, nuclear medicine, 49
processing methods, nuclear medicine images, 145
- COPD**. *see* Chronic obstructive pulmonary disease
- Cross-contamination**, prevention of, blood-labeling system for, 225
- Digital images**
computer acquisition of nuclear medicine images, 3
computer processing methods, nuclear medicine images, 145
- Dipyridamole**, common nonradioactive pharmaceutical listing, 240
- Dobutamine**, common nonradioactive pharmaceutical listing, 240
- Dopamine receptors**, I-123 IBZM imaging of, normal and schizophrenic subjects, 111(a)
- Dose calibrator**
assay of Ho-166 with, 109(a)
inaccuracies, short-lived radionuclides, 119(a)
measurement of Sr-89 with, 110(a)
radionuclide, positron emitters for evaluation of, 74
- Dose chart**
adjustment, radionuclide angiogram dose, 17
radionuclide angiogram, using linear equations, 105(ab)
- Drug utilization evaluation**, radiopharmaceuticals, 114(a)
- Dual-isotope acquisition**, computer processing methods, nuclear medicine images, 145
- Echocardiography**, simultaneous PET, ischemic cardiomyopathy patients, 106(ab)
- Enalaprilat**, common nonradioactive pharmaceutical listing, 240
- Epilepsy**, intractable, interictal perfusion brain SPECT in, pediatric patient, 112(a)
- Ethernet**, use in nuclear medicine, 49
- Filtered backprojection**, computer processing methods, nuclear medicine images, 145
- Filtering**, computer processing methods, nuclear medicine images, 145
- Fluorine-18**, evaluation, linearity of radionuclide dose calibrators, 74
- Fluorodeoxyglucose**
brain scans, attenuation correction method, 115(a)
PET
attenuation correction
improper contour placement in, 120(a)
pros and cons, 120(a)
septumless scanner, cancer scans with, 120(a)
production, variable water delivery and, 112(a)
SPECT imaging, triple-head, technical considerations, 108(a)
- Food and Drug Administration**, product defects or malfunctions, new program, 43
- Foot**, imaging, orthopaedic applications, 117(a)
- Furosemide**, common nonradioactive pharmaceutical listing, 240
- Gallium-67**
energy weighted and conventional acquisition for, 119(a)
inflammatory lung imaging, 127(a)

- Gallium-67 citrate**, detection, infected automatic internal cardiac defibrillator, 171
- Gamma camera**, acceptance testing, 58
- Gastric emptying**, Tc-99m MUFFIN study, 124(a)
- Gated acquisition**, computer processing methods, nuclear medicine images, 145
- Glomerular filtration rate**, determination, diagnostic methods, 126(a)
- Glucagon**, common nonradioactive pharmaceutical listing, 240
- Gonadotropin-releasing hormone**, vascular impact, cerebral and peripheral perfusion during hot flashes, 118(a)
- Health care reform**
in my opinion, 1
President Clinton's proposal, 42
- Heart**, PET imaging, alignment for, 104(ab)
- Hepatolite kit**, 261(le)
- Holmium-166**, assay with dose calibrator, 109(a)
- Hypertension**, renovascular, ACE inhibition scintigraphy, 129(a)
- Imaging**, upright, during a vasovagal episode, 63
- Indium-111 capromab pendetide**, monoclonal antibody imaging with, prostate cancer, 127(a)
- Indium-111 monoclonal antibody**
false positive findings during, colorectal carcinoma, 110(a)
PET, patients with metastatic disease, 121(a)
- Indium-111 OncoScint CR/OV**
high recovery yields of, careful filtration technique in, 70
imaging considerations with, 121(a)
- Indium-111 oxine**, platelet labeling, 222
- Indium-111 WBCs**, evaluation of osteomyelitis with, 118(a)
- In my opinion**, 1, 47, 143
- Iodine-131**
liquid, measurement for clinical application, 123(a)
serum albumin, isolation limb perfusion therapy, metastatic melanoma, 122(a)
therapy capsules, radiation safety concerns, 122(a)
thyroid therapy, camera-based thyroid uptake, 108(a)
whole-body studies, pulmonary uptake, 108(a)
- Iodine-123 IBZM**, imaging of dopamine receptors, normal and schizophrenic subjects, 111(a)
- Iodine-123 MIBG**, lung clearance, chronic heart failure patients, 104(ab)
- Kidney**
plasma flow determination, Tc-99m MAG3, 218
scintigraphy, Tc-99m DTPA and MAG3, 213
- Large field-of-view detectors**, emulation of small field-of-view detector, device for, 110(a)
- Liver**, scans, SPECT and CT study correlation, 65
- Liver transplant**, liver to cardiac functional activity evaluation, 129(a)
- Local area network (LAN)**, in nuclear medicine, 49
- Lung**
clearance of I-123 MIBG, chronic heart failure patients, 104(ab)
inflammatory, imaging with Ga-67, 127(a)
perfusion, gallbladder visualization on, 122(a)
- Lung scan**
preparation parameters for Tc-99m MAA-LPN, 173
quantitative, differential function calculations, 122(a)
- Lymphatic obstruction**, new radiopharmaceutical for use in detection, 106(ab)
- MedWatch**, FDA medical products reporting program, 43
- Melanoma**, metastatic, isolation limb perfusion therapy, I-131 serum albumin to evaluate, 122(a)
- Message from the president**, 2, 48, 144, 191
- Micro-aerosol**, commercial, versatility in, 119(a)
- Microwave**
heating techniques, preparation of Tc-99m sulfur colloid, 124(a)
ultrasafe preparation, Tc-99m cold kits, 114(a)
- Monoclonal antibodies**, radiolabeled, recovery of OncoScint CR/OV, 70
- Morphine**, common nonradioactive pharmaceutical listing, 240
- Myocardial perfusion**
exercise stress tests, drug usage evaluation, 105(ab)
quantitative processing protocol, 109(a)
simultaneous transmission and emission, triple head SPECT, 105(ab)
stress, false positive and negatives, 126(a)
- National Electrical Manufacturers Association (NEMA)**, gamma camera acceptance testing, 58
- Neonate**, lung scan, preparation parameters for Tc-99m MAA-LPN, 173
- Networks**, computer, local and wide area, use in nuclear medicine, 49
- Nitrogen-13**, evaluation, linearity of radionuclide dose calibrators, 74
- NMTCB**
eligibility requirements, 200
NMTCB examination, components of preparedness, 79
NMTCB report, 40, 95, 192
Normalization, PET, quality assurance procedures, 182
- Nuclear instrumentation**, guidelines for the technologist, 255
- Nuclear medicine**
automation of, computer-assisted, 110(a)
health care reform and, in my opinion, 1
- Nuclear medicine studies**, computers and, 3
- Nuclear medicine technology**
accredited programs, evolution, 236
guidelines for the technologist, 255
- Nuclear Regulatory Commission**, new Part 20 regulations, 250
- Osteomyelitis**
evaluation, Tc-99m IgG and In-111 WBCs, 118(a)
Tc-99m anti-granulocyte antibody imaging in, 126(a)
- Oxygen-15**
evaluation, linearity of radionuclide dose calibrators, 74
water production labeled with, radioactive gas releases after, 115(a)
- Parathyroid**, TL-201/Tc-99m images, computer analysis of, 118(a)
- Parathyroidectomy**, 3-dimensional localization, 125(a)
- Patient care**, guidelines for the technologist, 255
- Pediatric patients**
imaging, dedicated SPECT system with fanbeam collimators, 121(a)
intractable epilepsy, interictal perfusion brain SPECT in, 112(a)
- Pentagastrin**, common nonradioactive pharmaceutical listing, 240
- Phenobarbital**, common nonradioactive pharmaceutical listing, 240
- Planar images**, computer processing methods, nuclear medicine images, 145
- Platelet labeling**, In-111 oxine, 222
- Point source geometry**, intrinsic uniformity floods and calibrations, 127(a)
- Polycythemia**, red cell mass, radioisotopic determination of, 188
- Positron emission tomography (PET)**
attenuation correction
improper contour placement in, 120(a)
optimum scan length, 119(a)
brain, transmission-emission misalignment in, 115(a)
cardiac imaging, alignment for, 104(ab)
FDG, patients with metastatic disease, 121(a)
non-CNS tumors, 120(a)
quality assurance procedures, 27, 182
radiation safety considerations, 115(a)
radioligands, initial investigation of, 123(a)
simultaneous echocardiography, ischemic cardiomyopathy patients, 106(ab)
- Pregnancy**, radiation exposure in, lead apron use in, 107(a)
- Prostate cancer**, monoclonal antibody imaging, In-111 capromab pendetide, 127(a)
- Public exposure limit**, compliance, 107(ab)
- Pulmonary embolism**, unsuspected, ventilation imaging with pertechnegas in, 128(a)
- Pulmonary function testing**, nuclear cardiology laboratory, COPD patients, 105(ab)
- Quality assurance**
myocardial SPECT, cancellation of Tl-201 chloride, 232
PET, 27
PET procedures, 182
- Quality control**
guidelines for the technologist, 255
heat-damaged Tc-99m tagged human erythrocytes, 116(a)

- PET, 27
radiochemical purity testing, Tc-99m exametazime, 229
SPECT, ACNP corporate committee, 205
SPECT improvement, 35
Tc-99m bicusate, 113(a)
Tc-99m DMSA, 114(a)
thyroid images, pinhole, artifacts seen on, 109(a)
- Quantification techniques**, computer processing methods, nuclear medicine images, 145
- Radiation**
exposure
lead apron use in, 107(a)
PET center, 118(a)
shielding/safety considerations, 106(ab)
use of SESTAMIBI and, 117(a)
safety considerations
guidelines for the technologist, 198, 255
high energy beta-emitting Sr-89 chloride, 117(a)
I-131 therapy capsules
positron tomography center, 115(a)
- Radioactive gas**, release, after O-15 labeled water production, 115(a)
- Radioaerosols**, inhaled, carrier gas effects, 113(a)
- Radiochemical purity (RCP)**
Tc-99m bicusate, thin-layer chromatography, 21
testing, Tc-99m exametazime, 229
- Radioligands**, PET, initial investigation of, 123(a)
- Radionuclide angiogram dose (RNA)**
adjustment based on patient's physical parameters, 17
adjustment chart, using linear equations, 105(ab)
- Radionuclide contaminants**, in positron emitters, 74
- Radiopharmaceuticals**
guidelines for the technologist, 255
light-sensitive, 261(le)
- RBC kit**, anticoagulants in, comparison, 178
- Red blood cells**
anticoagulants with, comparison, 178
mass, radioisotopic determination of, 188
- Regions of interest**, computer processing methods, nuclear medicine images, 145
- Saline**, recovery of OncoScint CR/OV, 70
- Scintillation camera**, acceptance testing, 58
- Scintillation detection systems**, calculating minimal detectable activity for, 191(le)
- Scintimammography**
prone-dependent breast, 165
Tc-99, SESTAMIBI uptake, menstrual cycle correlation, 111(a)
- Single photon emission computed tomography (SPECT)**
bone, cervical spine, 107(a)
brain
automated iterative 3-dimensional, 108(a)
intractable epilepsy, pediatric, 112(a)
Tc-HMPAO, motion artifacts, 118(a)
fanbeam collimators with, pediatric imaging, 121(a)
FDG, triple-head, technical considerations, 108(a)
myocardial, cancellation of TI-201 chloride, 112(a)
versus planar sensitivity, bone metastasis, 126(a)
positive liver images, correlated with CT studies, 65
quality control, ACNP corporate committee, 205
quality improvement, 35
splenic images, confirmation of splenosis, 68
step and shoot versus continuous rotation, 109(a)
Tc-99m MDP and projection display comparison, 125(a)
TI-201 chloride, cancellation, 232
- Smoothing**, computer processing methods, nuclear medicine images, 145
- Spatial resolution**, PET, quality assurance procedures, 182
- Spleen**, scans, SPECT and CT study correlation, 65
- Splenosis**, SPECT images, 68
- Strontium-89**
computerized scheduling, clinical data management and, 111(a)
high energy beta-emitting radiotherapy, radiation safety of, 117(a)
measurement, dose calibrator, 110(a)
technical aspects, 117(a)
therapy, painful bony metastases, 39(le)
- Strontium-89 chloride**, pain relief, bone metastasis, 126(a)
- Tauxe method**, renal plasma flow determination, 218
- Technetium-99m**
cold kits, ultrasonic microwave preparation of, 114(a)
energy weighted and conventional acquisition for, 119(a)
radiopharmaceuticals labeled with, brain retention mechanism in, 114(a)
- Technetium-99m albumin colloid**, vs Tc-99m sulfur colloid, gastric emptying studies, 129(a)
- Technetium-99m anti-granulocyte antibody**, osteomyelitis, 126(a)
- Technetium-99m bicusate**
characterization of, thin-layer chromatographic procedures for, 21
rapid quality control procedure for, 113(a)
- Technetium-99mBrIDA**, utilization evaluation, 114(a)
- Technetium-99m DMSA**
labeling of, chemical parameters in, 123(a)
preparation and quality control, 114(a)
- Technetium-99m DTPA**, sequential injections, renal scintigraphy, 213
- Technetium-99m furifosmin**, myocardial imaging, performance parameters, 124(a)
- Technetium-99m HMPAO**, brain SPECT, motion artifacts in, 118(a)
- Technetium-99m IgG**, evaluation of osteomyelitis with, 118(a)
- Technetium-99m MAA**, utilization evaluation, 114(a)
- Technetium-99m MAA-LPN**, preparation parameters for, 173
- Technetium-99m MAG3**
blood sampling and, use of one catheter for both, 112(a)
clearance, methods for measurement of, 111(a)
ERPF calculations, 123(a)
plasma flow determination with, renal, 218
sequential injections, renal scintigraphy, 213
transient renal hypoperfusion, during a vasovagal episode, 63
- Technetium-99m MDP**
bone scintigraphy, finding of gastrointestinal bleeding on, 14
diagnosis of primary breast cancer, technician role in, 111(a)
SPECT and projection display comparison, rib lesions, 125(a)
uptake, breast pocket sign, 211
- Technetium-99m mebrofenin**, correct shelf life, 39(le)
- Technetium-99m monoclonal antibodies**, colon cancer patients injected with, 120(a)
- Technetium-99m MUFFIN**, gastric emptying study, 124(a)
- Technetium-99m RBC**
anticoagulant comparison, red blood cell kit, 178
heat-damaged, quality control for, 116(a)
needleless technique kit, gated blood pool imaging, 106(ab)
- Technetium-99m SESTAMIBI**
bilateral increased uptake, scintimammography, 111(a)
prone-dependent breast scintimammography, 165
radiation exposure subsequent to, 117(a)
- Technetium-99m sulfur colloid**
detection of lymphatic obstruction, 106(ab)
preparation, microwave heating techniques for, 124(a)
- SPECT**
liver/spleen images, 65
splenic images, 68
vs Tc-99m albumin colloid, gastric emptying studies, 129(a)
- Technetium-99m tetrofosmin**, chromatographic evaluation of, 113(a)
- Technitium-99m exametazime**, standard radiochemical purity testing, 229
- Technologist News**, 42, 97, 194
- Thallium-201**, Tc-99m SESTAMIBI comparison, breast tumor imaging, 121(a)
- Thallium-201 chloride**
myocardial SPECT, solving cancellation of, 112(a)
SPECT, myocardial, cancellation of, 232
- Thrombocytopenia**, In-111 platelet labeling, 222
- Thyroid**, therapy, camera-based uptake measurements, 108(a)
- Thyroid carcinoma**, I-131 uptake, pulmonary, 108(a)
- Token-Ring**, use in nuclear medicine, 49
- Transmission-emission misalignment**, brain PET, 115(a)

Vasovagal episode, transient renal hypoperfusion during, 63
Ventilation scans, Xe-133, intubated patients, 122(a)
Vitamin B-12, common nonradioactive pharmaceutical listing, 240

Weight, dose adjustment by, radionuclide angiogram dose, 17
White blood cell labeling, Hetastarch and Dextran-70 use in, 127(a)
Wide area network, in nuclear medicine, 49

Xenon-133
ventilation scans, intubated patients, 122(a)
washout, pulmonary function and, evaluation of COPD, 113(a)